Completed PHASE4 INTERVENTIONAL 3-arm NCT01456780

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis (ZvL)

Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis

Sponsor: Bausch & Lomb Incorporated

Conditions Meibomian Gland Dysfunction Posterior Blepharitis

Interventions B+L Advanced Eye Relief Lubricant Drop Loteprednol Loteprednol/tobramycin

Updated 7 times since 2017 Last updated: Jul 6, 2017 Started: Aug 31, 2011 Primary completion: Mar 31, 2013 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Meibomian Gland Dysfunction and Posterior Blepharitis, this trial is completed. The trial is conducted by Bausch & Lomb Incorporated and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Sep 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Aug 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated
Massachusetts Eye and Ear Infirmary

Data source: Massachusetts Eye and Ear Infirmary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States